💎 Fed’s first rate cut since 2020 set to trigger market. Find undervalued gems with Fair ValueSee Undervalued Stocks

Neothetics' lead product candidate flunks mid-stage study; shares plummet 68% premarket

Published 06/26/2017, 09:19 AM
© Reuters.  Neothetics' lead product candidate flunks mid-stage study; shares plummet 68% premarket
EVFM
-
  • Thinly traded nano cap Neothetics (NASDAQ:NEOT) craters 68% premarket on robust volume in response to its announcement that a Phase 2 clinical trial assessing lead product candidate LIPO-202-CL-31 for reducing submental subcutaneous fat (double chin) failed to show a treatment effect greater than placebo.
  • The company says it is disappointed with the outcome and is "determining a path forward for the company." At the end of Q1, its cash balance was only $9.7M.
  • LIPO-202 is an injectable formulation of salmeterol xinafoate, a well-known long-acting beta2-adrenergic receptor agonist used in several commercially available inhaled drugs, including GlaxoSmithKline's SEREVENT DISKUS. Earlier studies suggested that salmeterol xinafoate activates beta2-adrenergic receptors in fat cells, triggering the metabolism of triglycerides and shrinking them via a process called lipolysis.
  • Previously: Neothetics initiates mid-stage study of lead product candidate for reduce double chin; shares ahead 21% premarket (Dec. 23, 2016)
  • Now read: Trading in Neothetics halted pending news


Original article

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.